Immune globulin - Therapure Biopharma

Drug Profile

Immune globulin - Therapure Biopharma

Alternative Names: 10% intravenous immunoglobulin - Therapure Biopharma; Human immunoglobulin - Therapure Biopharma; Intravenous immunoglobulin - Therapure Biopharma; PlasmaCap IG; Therapure PlasmaCap IG

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Therapure Biopharma
  • Class Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Immunodeficiency disorders

Most Recent Events

  • 05 Sep 2017 Phase-III clinical trials in Immunodeficiency disorders (In infants, In children, In adolescents, In adults, In the elderly) in USA (IV) (NCT03238079)
  • 05 Aug 2017 Therapure Biopharma plans a phase III trial for Immunodeficiency disorders (In children, In adolescents, In adults, In the elderly) in USA (IV) in August 2017 (NCT03238079)
  • 05 Aug 2017 Preclinical trials in Immunodeficiency disorders in USA (IV), before August 2017 (Therapure Biopharma website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top